How the TMX1 protein helps prevent dangerous blood clots
The Transmembrane Protein Disulfide Isomerase TMX1 Negatively Regulates Thrombosis
This research looks at whether the TMX1 protein keeps platelets and blood vessels from forming harmful clots to help people at risk of thrombosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11248752 on NIH RePORTER |
What this research studies
This work focuses on a protein called TMX1 that sits on platelets and cells lining blood vessels and appears to slow down clot formation. Scientists will compare TMX1 to related proteins that promote clotting and use laboratory experiments with platelets, vessel cells, and model systems to see how TMX1 changes blood clot behavior. The team aims to understand the exact chemical steps TMX1 uses to limit platelet activation and fibrin formation. The findings could point toward new ways to prevent clots with less bleeding risk than current treatments.
Who could benefit from this research
Good fit: People with a history of arterial or venous thrombosis, or those at high risk for blood clots, would be the most likely candidates to benefit from future trials based on this work.
Not a fit: People without clotting problems or whose conditions are unrelated to platelet-driven thrombosis may not see direct benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies or drug targets that reduce dangerous blood clots while lowering bleeding side effects.
How similar studies have performed: Other studies of the protein disulfide isomerase (PDI) family have shown those proteins can promote clotting, but TMX1 appears novel because it acts in the opposite, anti-clotting direction and is less well studied.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Essex, David W — Temple Univ of the Commonwealth
- Study coordinator: Essex, David W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.